Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma

Proteomics

Volumn 12, Issue 23-24, 2012, Pages 3590-3597

  Park, Hyung Doo ^a   Kang, Eun Suk ^a   Kim, Jong Won ^a   Lee, Kyu Taek ^a   Lee, Kwang Hyuck ^a   Park, Young Suk ^a   Park, Joon Oh ^a   Lee, Jeeyun ^a   Heo, Jin Seok ^b   Choi, Seong Ho ^b   Choi, Dong Wook ^b   Kim, Seonwoo ^b   Lee, Jong Kyun ^a   Lee, Soo Youn ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Biomedicine; Multiplexing; Pancreatic cancer; Serum biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CATHEPSIN D; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CATHEPSIN D; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; PANCREATIC DUCTS; PANCREATIC NEOPLASMS;

EID: 84871262748     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200101     Document Type: Article

References (40)

1. Brandt, R., Grutzmann, R., Bauer, A., Jesnowski, R. et al., DNA microarray analysis of pancreatic malignancies. Pancreatology 2004, 4, 587-597.
2. Yeo, C. J., Cameron, J. L., Lillemoe, K. D., Sitzmann, J. V. et al., Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann. Surg. 1995, 221, 721-731.
3. Nishida, K., Kaneko, T., Yoneda, M., Nakagawa, S. et al., Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J. Surg. Oncol. 1999, 71, 140-146.
4. Ishii, H., Okada, S., Sato, T., Wakasugi, H. et al., CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997, 44, 279-283.
5. Hess, V., Glimelius, B., Grawe, P., Dietrich, D. et al., CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet. Oncol. 2008, 9, 132-138.
6. Goggins, M., Identifying molecular markers for the early detection of pancreatic neoplasia. Semin. Oncol. 2007, 34, 303-310.
7. Rosty, C., Goggins, M., Early detection of pancreatic carcinoma. Hematol. Oncol. Clin. North Am. 2002, 16, 37-52.
8. Kim, B. J., Lee, K. T., Moon, T. G., Kang, P. et al., How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Digest. Liver Dis. 2009, 41, 364-369.
9. Tanase, C. P., Neagu, M., Albulescu, R., Hinescu, M. E., Advances in pancreatic cancer detection. Adv. Clin. Chem. 2010, 51, 145-180.
10. Harsha, H. C., Kandasamy, K., Ranganathan, P., Rani, S. et al., A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009, 6, e1000046.
11. Hustinx, S. R., Cao, D., Maitra, A., Sato, N. et al., Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer. Biol. Ther. 2004, 3, 1254-1261.
12. Whiteman, H. J., Weeks, M. E., Dowen, S. E., Barry, S. et al., The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res. 2007, 67, 8633-8642.
13. Johnson, M. D., Torri, J. A., Lippman, M. E., Dickson, R. B., The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res. 1993, 53, 873-877.
14. Mroczko, B., Lukaszewicz-Zajac, M., Wereszczynska-Siemiatkowska, U., Groblewska, M. et al., Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009, 38, 613-618.
15. Bloomston, M., Shafii, A., Zervos, E. E., Rosemurgy, A. S., TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J. Surg. Res. 2002, 102, 39-44.
16. Jones, L. E., Humphreys, M. J., Campbell, F., Neoptolemos, J. P., Boyd, M. T., Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin. Cancer Res. 2004, 10, 2832-2845.
17. Bramhall, S. R., Neoptolemos, J. P., Stamp, G. W., Lemoine, N. R., Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J. Pathol. 1997, 182, 347-355.
18. Gress, T. M., Muller-Pillasch, F., Lerch, M. M., Friess, H. et al., Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int. J. Cancer 1995, 62, 407-413.
19. Li, Y. J., Wei, Z. M., Meng, Y. X., Ji, X. R., Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J. Gastroenterol. 2005, 11, 2117-2123.
20. Bloomston, M., Zervos, E. E., Rosemurgy, A. S., 2nd, matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann. Surg. Oncol. 2002, 9, 668-674.
21. Friess, H., Ding, J., Kleeff, J., Fenkell, L. et al., Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell. Mol. Life Sci. 2003, 60, 1180-1199.
22. Streit, S., Michalski, C. W., Erkan, M., Friess, H., Kleeff, J., Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative RT-PCR. Pancreatology 2009, 9, 577-582.
23. Hoboken NJ, Wiley-Liss, Wiley J, TNM-Atlas: Illustrated Guide to the TNM Classification of Malignant Tumors. Springer-Verlag, Berlin 2005.
24. Robin, X., Turck, N., Hainard, A., Tiberti, N. et al., pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011, 12, 77.
25. Mercaldo, N. D., Lau, K. F., Zhou, X. H., Confidence intervals for predictive values with an emphasis to case-control studies. Stat. Med. 2007, 26, 2170-2183.
26. Harada, T., Chelala, C., Crnogorac-Jurcevic, T., Lemoine, N. R., Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology 2009, 9, 13-24.
27. Binkley, C. E., Zhang, L., Greenson, J. K., Giordano, T. J. et al., The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 2004, 29, 254-263.
28. Reni, M., Cereda, S., Balzano, G., Passoni, P. et al., Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009, 115, 2630-2639.
29. Tumminello, F. M., Leto, G., Pizzolanti, G., Candiloro, V. et al., Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res. 1996, 16, 2315-2319.
30. Duffy, M. J., Proteases as prognostic markers in cancer. Clin. Cancer Res. 1996, 2, 613-618.
31. Liaudet-Coopman, E., Beaujouin, M., Derocq, D., Garcia, M. et al., Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett. 2006, 237, 167-179.
32. Chen, R., Brentnall, T. A., Pan, S., Cooke, K. et al., Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell Proteomics 2007, 6, 1331-1342.
33. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L., Li, D., Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004, 64, 9018-9026.
34. Liotta, L. A., Stetler-Stevenson, W. G., Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 1991, 51, 5054s-5059s.
35. Yeh, Y. C., Sheu, B. S., Cheng, H. C., Wang, Y. L. et al., Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig. Dis. Sci. 2010, 55, 1649-1657.
36. Heslin, M. J., Yan, J., Johnson, M. R., Weiss, H. et al., Role of matrix metalloproteinases in colorectal carcinogenesis. Ann. Surg. 2001, 233, 786-792.
37. Szarvas, T., Becker, M., vom Dorp, F., Gethmann, C. et al., Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 2010, 101, 1300-1308.
38. Fang, Y. J., Lu, Z. H., Wang, G. Q., Pan, Z. Z. et al., Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int. J. Colorectal Dis. 2009, 24, 875-884.
39. Sawey, E. T., Johnson, J. A., Crawford, H. C., Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc. Natl. Acad. Sci. USA 2007, 104, 19327-19332.
40. Joergensen, M. T., Brunner, N., De Muckadell, O. B., Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res., 30, 587-592.